vs

Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and MEDIFAST INC (MED). Click either name above to swap in a different company.

CareTrust REIT, Inc. is the larger business by last-quarter revenue ($134.9M vs $75.1M, roughly 1.8× MEDIFAST INC). On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs -36.9%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs -34.4%).

Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

CTRE vs MED — Head-to-Head

Bigger by revenue
CTRE
CTRE
1.8× larger
CTRE
$134.9M
$75.1M
MED
Growing faster (revenue YoY)
CTRE
CTRE
+92.0% gap
CTRE
55.1%
-36.9%
MED
Faster 2-yr revenue CAGR
CTRE
CTRE
Annualised
CTRE
46.2%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTRE
CTRE
MED
MED
Revenue
$134.9M
$75.1M
Net Profit
$111.3M
Gross Margin
69.4%
Operating Margin
-10.4%
Net Margin
82.5%
Revenue YoY
55.1%
-36.9%
Net Profit YoY
113.5%
EPS (diluted)
$0.52
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTRE
CTRE
MED
MED
Q4 25
$134.9M
$75.1M
Q3 25
$132.4M
$89.4M
Q2 25
$112.5M
$105.6M
Q1 25
$96.6M
$115.7M
Q4 24
$86.9M
$119.0M
Q3 24
$77.4M
$140.2M
Q2 24
$68.9M
$168.6M
Q1 24
$63.1M
$174.7M
Net Profit
CTRE
CTRE
MED
MED
Q4 25
$111.3M
Q3 25
$74.9M
$-2.3M
Q2 25
$68.5M
$2.5M
Q1 25
$65.8M
$-772.0K
Q4 24
$52.1M
Q3 24
$33.4M
$1.1M
Q2 24
$10.8M
$-8.2M
Q1 24
$28.7M
$8.3M
Gross Margin
CTRE
CTRE
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
CTRE
CTRE
MED
MED
Q4 25
-10.4%
Q3 25
58.1%
-4.6%
Q2 25
61.3%
-1.0%
Q1 25
-1.1%
Q4 24
0.6%
Q3 24
43.0%
1.5%
Q2 24
15.1%
-4.7%
Q1 24
4.5%
Net Margin
CTRE
CTRE
MED
MED
Q4 25
82.5%
Q3 25
56.6%
-2.5%
Q2 25
60.9%
2.3%
Q1 25
68.1%
-0.7%
Q4 24
60.0%
Q3 24
43.2%
0.8%
Q2 24
15.6%
-4.8%
Q1 24
45.6%
4.8%
EPS (diluted)
CTRE
CTRE
MED
MED
Q4 25
$0.52
$-1.64
Q3 25
$0.35
$-0.21
Q2 25
$0.35
$0.22
Q1 25
$0.35
$-0.07
Q4 24
$0.30
$0.08
Q3 24
$0.21
$0.10
Q2 24
$0.07
$-0.75
Q1 24
$0.22
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTRE
CTRE
MED
MED
Cash + ST InvestmentsLiquidity on hand
$198.0M
$167.3M
Total DebtLower is stronger
$894.2M
Stockholders' EquityBook value
$4.0B
$198.9M
Total Assets
$5.1B
$248.0M
Debt / EquityLower = less leverage
0.22×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTRE
CTRE
MED
MED
Q4 25
$198.0M
$167.3M
Q3 25
$712.5M
$173.5M
Q2 25
$306.1M
$162.7M
Q1 25
$26.5M
$164.6M
Q4 24
$213.8M
$162.3M
Q3 24
$377.1M
$170.0M
Q2 24
$495.1M
$163.5M
Q1 24
$451.2M
$156.4M
Total Debt
CTRE
CTRE
MED
MED
Q4 25
$894.2M
Q3 25
$893.8M
Q2 25
$1.2B
Q1 25
$822.1M
Q4 24
$396.9M
Q3 24
$396.7M
Q2 24
$671.1M
Q1 24
$595.9M
Stockholders' Equity
CTRE
CTRE
MED
MED
Q4 25
$4.0B
$198.9M
Q3 25
$4.0B
$214.7M
Q2 25
$3.3B
$216.0M
Q1 25
$2.9B
$211.0M
Q4 24
$2.9B
$210.1M
Q3 24
$2.4B
$207.3M
Q2 24
$1.9B
$205.3M
Q1 24
$1.7B
$211.0M
Total Assets
CTRE
CTRE
MED
MED
Q4 25
$5.1B
$248.0M
Q3 25
$5.1B
$268.2M
Q2 25
$4.7B
$269.3M
Q1 25
$3.9B
$280.0M
Q4 24
$3.4B
$284.2M
Q3 24
$2.9B
$291.2M
Q2 24
$2.7B
$293.5M
Q1 24
$2.3B
$302.8M
Debt / Equity
CTRE
CTRE
MED
MED
Q4 25
0.22×
Q3 25
0.22×
Q2 25
0.35×
Q1 25
0.28×
Q4 24
0.14×
Q3 24
0.16×
Q2 24
0.35×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTRE
CTRE
MED
MED
Operating Cash FlowLast quarter
$394.0M
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
3.54×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTRE
CTRE
MED
MED
Q4 25
$394.0M
$-5.3M
Q3 25
$100.9M
$12.1M
Q2 25
$100.8M
$-3.4M
Q1 25
$71.4M
$3.4M
Q4 24
$244.3M
$-4.9M
Q3 24
$67.2M
$9.1M
Q2 24
$53.0M
$13.1M
Q1 24
$48.8M
$7.3M
Free Cash Flow
CTRE
CTRE
MED
MED
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
CTRE
CTRE
MED
MED
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
CTRE
CTRE
MED
MED
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
CTRE
CTRE
MED
MED
Q4 25
3.54×
Q3 25
1.35×
Q2 25
1.47×
-1.36×
Q1 25
1.08×
Q4 24
4.68×
Q3 24
2.01×
8.04×
Q2 24
4.92×
Q1 24
1.70×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons